← Back to Search

Activity Monitoring for Lung Cancer

N/A

Recruiting

Led By Nitin Ohri, MD

Research Sponsored by NRG Oncology

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG Performance Status 0-3 within 30 days prior to registration

Pathologically (histologically or cytologically) proven diagnosis of NSCLC

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from study enrollment to 1 month after radiotherapy completion.

Awards & highlights

Study Summary

This trial will track daily steps of people with lung cancer to improve care and reduce adverse events during radiation treatment.

Who is the study for?

This trial is for adults with a confirmed diagnosis of non-small cell lung cancer (NSCLC) who are about to start chemoradiotherapy. They should be able to walk independently or with a cane, have an ECOG Performance Status of 0-3, and not be receiving other systemic therapies like immunotherapy. Participants must consent to the study and agree to wear the Garmin Vivofit Activity Tracker.Check my eligibility

What is being tested?

The trial is testing whether using a Garmin Vivofit Activity Tracker to monitor daily steps can help doctors provide better care during chemoradiotherapy for NSCLC by potentially reducing adverse events related to treatment.See study design

What are the potential side effects?

Since this trial involves monitoring activity rather than testing a new drug, there are no direct side effects from the intervention itself. However, participants will still experience side effects from their standard lung cancer treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been mostly active and able to care for myself in the last month.

Select...

My lung cancer diagnosis was confirmed through lab tests.

Select...

I can walk on my own or with a cane.

Select...

I am 18 years old or older.

Select...

I will start chest radiotherapy with chemotherapy within 30 days after joining the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from study enrollment to 1 month after radiotherapy completion.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from study enrollment to 1 month after radiotherapy completion.

This trial's timeline: 3 weeks for screening, Varies for treatment, and from study enrollment to 1 month after radiotherapy completion. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Occurrence of emergency room visit lasting more than 24 hours

Occurrence of hospital admission

Therapeutic radiology procedure

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm II: Usual Care + Continuous physical activity monitoring via a wearable deviceExperimental Treatment1 Intervention

Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.

Group II: Arm I: Usual CareActive Control1 Intervention

Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

NRG OncologyLead Sponsor

231 Previous Clinical Trials

100,708 Total Patients Enrolled

Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program (PA CURE)UNKNOWN

Nitin Ohri, MDPrincipal InvestigatorNRG Oncology

6 Previous Clinical Trials

327 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this research endeavor for participants?

"Affirmative. Clinicaltrials.gov confirms that this research is in the process of participant recruitment, after being first posted on September 10th 2023 and last updated October 24th 2023. The study requires 144 people to be recruited from one location."

Answered by AI

What is the overall size of the group participating in this experiment?

"Affirmative. According to clinicaltrials.gov, this medical trial was posted on September 10th 2023 and most recently updated on October 24th of the same year; its primary objective is to recruit 144 subjects from one location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

2024. "Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04878952.